Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Comparisons of CT features and <sup>18</sup>F-FDG metabolic indices between benign and malignant entities, as well as among primary and secondary malignancies and lymphoma, were performed.
|
31807883 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A 65-year-old man underwent FDG PET/CT for evaluation of vertebral lesions, radiologically suspected to be metastases.
|
31652162 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We retrospectively reviewed F-FDG PET/CT studies of 117 patients (169 lesions), of which 65 had imaging of enostoses, and 52 had imaging showing the transition of lesions from untreated to treated osteoblastic metastases.
|
31693615 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of this study is to prospectively evaluate the performance of sodium <sup>18</sup>F]fluoride (Na[<sup>18</sup>F]F)/2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers.
|
31236756 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Comparison of <sup>18</sup>F-FDG PET/MRI, MRI, and <sup>18</sup>F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma.
|
31606831 |
2020 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
[<sup>18</sup>F]Fluorodeoxyglucose ([<sup>18</sup>F]FDG) Positron emission tomography/computed tomography (PET/CT) is commonly used for rectal cancer staging, but improved diagnostic methods for nodal metastases are needed.
|
30899056 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A range of parameters including volumetric and heterogeneity measures were derived from FDG PET images of 52 patients with colorectal intrahepatic-only metastases (29 males and 23 females; mean age 62.9 years [SD 9.8; range 32-82]).
|
30927933 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The FDG pattern resembled as a cIV stage vulvar cancer, whereas biopsy indicated metastases from breast cancer.
|
30985415 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
This study assesses <sup>18</sup>F-FDG PET/CT systemic staging in patients with newly diagnosed male breast cancer and determines detection rates for unsuspected distant metastases stratified by pre-PET/CT stage.
|
30237211 |
2019 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Conclusions and significance:</b><sup>18</sup>F-FDG PET/CT or conventional imaging is comparable with regard to detecting distant metastases of recurrent HNSCC.
|
31274365 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>18</sup> F-FDG PET/MRI is superior to MRI in detecting local recurrence and metastases in patients with ACC of the head and neck.
|
30548894 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
SUV<sub>max</sub> ratio between the cardiac focus and surrounding background cardiac uptake and status of distant metastases might help to differentiate malignant from benign nature of the focal cardiac uptake on FDG PET/CT.
|
30443752 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
No differences between metachronous cancers and metastases were found in: patient's age (70.3±8.1years vs 69.5±9.7years), gender (males=63.1% vs 62.5%), interval between previous cancer diagnosis and nodules' detection (median time=4years vs 4.5years), location (right-lung=55% vs 54%; upper-lobes=64% vs 67%; central-site=31% vs 25%), size (median size=17mm vs 19.5mm), 18F-FDG standardized uptake value (median SUVmax=5.2 vs 5.9).
|
30654605 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Vice versa, highly F-FDG-avid lung lesions in patients with brain tumors should lead to distant metastases as differential diagnosis despite their rare occurrence.
|
31584491 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Data from studies comparing PET/MRI and PET/CT for staging/restaging suggested the superiority of <sup>18</sup>F-FDG PET/MRI for the detection of tumour extension and retropharyngeal lymph node metastases in nasopharyngeal cancer, and for the detection of liver metastases and possibly bone marrow metastases in high-risk BC.
|
31267161 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
However, <sup>18</sup>F-FDG PET/CT is useful for the detection of interval metastases and might become useful in an active surveillance strategy with serial <sup>18</sup>F-FDG PET/CT scanning.
|
30877177 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We present a case of non-small cell lung cancer with myocardial and pericardial metastases obscured by physiologic F-FDG cardiac uptake but detected with the investigational PET radiotracer (4S)-4-(3-F-fluoropropyl)-L-glutamate (F-FSPG), which targets a pathway associated with glutathione biosynthesis.
|
29076915 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Mazabraud's Syndrome Mimicking Metastases on FDG PET/CT in a Patient With Colon Cancer.
|
29863575 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that <sup>18</sup>F-FDG PET/CT may be of great value in identifying metastases in postoperative DTC patients with elevated ssTg before <sup>131</sup>I administration, leading to an improved management of disease.
|
29531251 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The sensitivity and accuracy of <sup>18</sup> F-FDG PET/CT for the detection of distant metastases were significantly higher than those of CT (p < 0.05), whereas, for detection of loco-regional recurrences, they did not differ (p > 0.1).
|
29688610 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The <sup>18</sup>F-FDG PET/CT bone scan was much better in diagnosing metastases compared to the <sup>99m</sup>Tc-MDP scan.
|
29177262 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The sensitivity and specificity for F-FDG PET/CT and CECT to detect metastases were 68% and 100% and 64% and 93%, respectively.
|
29485442 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The secondary outcome measure was the proportion of patients in whom 18F-FDG PET(/CT) restaging was false positive for distant interval metastases (i.e. false positives).
|
29917073 |
2018 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Similarly, pooled specificity was comparable with CT (93%) or without 95% (P = .481).F-FDG PET, with or without CT, shows relatively low sensitivity but high specificity for diagnosing extrahepatic metastases or local residual/recurrent HCC.
|
30142825 |
2018 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The multiple lesions gradually progressed, and FDG-PET/CT subsequently revealed additional metastases in the liver and perineum.
|
29879077 |
2018 |